Precision oncology: an overview.

@article{Garraway2013PrecisionOA,
  title={Precision oncology: an overview.},
  author={Levi A. Garraway and Jaap Verweij and Karla V. Ballman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 15},
  pages={
          1803-5
        }
}
  • L. Garraway, J. Verweij, K. Ballman
  • Published 20 May 2013
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In this Special Series issue, Journal of Clinical Oncology presents a systematic assessment of cancer genomic information and its accelerating clinical impact. In the scientific literature and lay press, the relevant discipline is often called personalized, or precision, cancer medicine. The word personalized conveys the sense that cancer genomic data may facilitate rational treatment choices that are tailored to individual patients. The term precision refers to prospects for enhanced molecular… 
Precision medicine in oncology – On a journey from dreams to reality
Precision medicine is defined as treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given
Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.
TLDR
Tissue banking has expanded from its traditional base in academic research and is assuming an increasingly pivotal role in directing the clinical care of cancer patients and molecular testing and precision medicine clinical trials are now becoming the major thrust behind the cooperative groups' clinical research efforts.
Precision oncology in urothelial cancer
TLDR
An overview on clinically-impactful discoveries in urothelial cancer is presented, the limitations and challenges in the implementation of precision oncology are discussed, and the vision for its future is offered.
Incorporating Genomics into Breast Cancer Clinical Trials and Care
TLDR
Significant other challenges remain before these technologies can be successfully implemented in the clinic, including the predictive accuracy of pathway-based models, distinguishing drivers from passenger mutations, development of rational combinations, addressing genomic heterogeneity, and molecular evolution/resistance mechanisms.
Pragmatic medicine in solid cancer: a translational alternative to precision medicine
TLDR
Overall, this work supports a pragmatic, multidisciplinary, and collaborative R&D, and suggests that direction be set by clinical need and utility, and by questions, not answers.
Introduction and overview to issue on new developments in pediatric hematology/oncology.
  • E. Raetz
  • Medicine
    Current opinion in pediatrics
  • 2015
TLDR
The articles in this issue highlight examples of recent progress and the potential impact, as well as the associated challenges, of the movement toward precision medicine for children with a spectrum of oncologic diseases and nonmalignant disorders.
Translating cancer genomes and transcriptomes for precision oncology
TLDR
Key applications and new directions are outlined for translating the cancer genome and transcriptome into patient care in the clinic in a review of next‐generation DNA sequencing technologies.
Precision Medicine in Pediatric Oncology- Is it the Way Forward?
TLDR
The diagnostic and therapeutic advancements along with some of the important clinical implications and the future prospects of precision medicine in pediatric oncology are discussed.
An integrated clinical and genomic information system for cancer precision medicine
TLDR
This work presents an integrated clinical and genomic information system (CGIS) based on NGS data analyses that built a comprehensive knowledgebase of genes, variants, drugs by collecting annotated information from public and in-house resources.
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
TLDR
The PanDrugs tool represents the first drug prescription strategy applying a rational based on pathway context, multi-gene markers impact and information provided by functional experiments to guide the selection of personalized treatments in cancer patients using the variant lists provided by genome-wide sequencing analyses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Personalizing oncology: perspectives and prospects.
  • J. Mendelsohn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
This article provides an overview of the research, beginning a century ago, that has led to the current use of genomically informed methods for selection of targeted therapies to treat individual
Genomics-driven oncology: framework for an emerging paradigm.
  • L. Garraway
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
Evaluation of this genomics-driven cancer medicine hypothesis will require many logistic innovations that are guided by overarching conceptual advances in tumor genomic profiling, data interpretation, clinical trial design, and the ethical return of genetic results to oncologists and their patients.
Advancing precision medicine for prostate cancer through genomics.
TLDR
P predictive biomarker candidates involving ETS gene rearrangements, PTEN inactivation, and androgen receptor signaling, and other putative biomarkers may signify aberrant oncogene pathway activation and provide a rationale for matching patients with molecularly targeted therapies in clinical trials are reviewed.
Designing transformative clinical trials in the cancer genome era.
TLDR
An overview of the emerging methodologic challenges in the cancer genome era is provided and some potential solutions for transforming clinical trial designs so they can identify new active anticancer regimens in molecularly defined subgroups as efficiently as possible are offered.
Future of clinical genomics in pediatric oncology.
TLDR
Through large-scale molecular profiling of pediatric tumors, continued coordinated efforts to evaluate novel therapies in the pediatric population, thoughtful phase II and III trial design, and continued drug development, genomically based therapies will become more common in the Pediatrics oncology clinic in the future.
Genomic medicine frontier in human solid tumors: prospects and challenges.
TLDR
A historical view of how increased understanding of cancer genomics has been translated to the clinic is presented and the prospects and challenges for further implementation of a personalized treatment strategy for human solid tumors are discussed.
Building a personalized medicine infrastructure at a major cancer center.
TLDR
The building of infrastructure for personalized cancer therapy requires a major investment in infrastructure to facilitate rapid deployment of multiplex, cost-effective, and tissue-sparing assays relevant across multiple tumor lineages in the CLIA environment.
Leveraging cancer genome information in hematologic malignancies.
  • R. Rampal, R. Levine
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
Recent major genetic advances in myeloid and lymphoid malignancies, the impact of these findings on prognostic models, the authors' understanding of disease initiation and evolution, and the implication of genomic discoveries on clinical decision making are reviewed.
Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.
TLDR
Six conceptual paradigms are summarized that illustrate the transition from empirical cancer medicine to mechanistically based individualized oncology.
Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology.
TLDR
The ethical, legal, and counseling issues surrounding disclosure of genetic information generated by NGS to patients with cancer and their relatives are discussed and a framework for returning these genetic results is provided by proposing a design for a qualified disclosure policy.
...
1
2
...